Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROC-SpA: Rotation or Change of Biotherapy After TNF Blocker Failure in Axial Spondyloarthritis
2017-004700-22Phase 4Completed
- Sponsor
- CHU Saint-Etienne
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of secukinumab in axial spondyloarthritis (axSpA) (2 arms), sponsored by CHU Saint-Etienne. Primary endpoint: ASAS40 response at week 24. Started Jan 2018; status: completed.
02
Drugs
secukinumab
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on 2017-004700-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004700-22.